At @BenCanMag Canadian Leadership Council on Drug Plan Partnerships we brought together plan advisors to discuss innovation in drug development and its impact on Canadian private drug plans. Would love to hear your thoughts.
https://t.co/YYjC8wJqeg
The Plan Sponsor's Guide to Rare Diseases addresses many of the issues that impact Canadian private plans. I learned a lot by working on this and hope you do too. https://t.co/GH3C562VN1 via @BenCanMag#RareDisease#benefits
At Express Scripts Canada, we're tracking medications and technologies that improves the health of Canadians. If you'd like an in-depth view, download your copy of our 2022 Drug Trend Report here: https://t.co/v6Q2Pr3qtE
#HR#PBM#Benefits#TPA
Gene therapies could reshape the way genetic diseases are managed because they target the underlying cause of genetic disease rather than just treating complex medical conditions. I learned a lot writing this for @BenCanMag and I hope you do to. https://t.co/5kxCUpWDco
My article in the November 2021 issue of IQVIA PRA includes profiles of several Canadian private payers to help PRA subscribers improve partnerships, submissions and ongoing collaborations. @IQVIA
PGx testing may be included in employee benefits plans; however, there is significant variability between providers and tests. This guide gives practical guidance on selecting a provider. I learned a lot working on this project, and I hope you do too.
https://t.co/8XVr1lRYxZ
The PLAN SPONSORS GUIDE TO DIABETES provides education and resources on how to support plan members living with diabetes or caregivers of people with diabetes. I learned so much writing this guide, and I hope you do too!
https://t.co/Bs6pijvdAk
@SuzanneLepage & Lindy Forte provide thoughtful insight into the importance of transparency in the Private Payer's HTA process at today's #CADTHSymp breakfast session.
.@BenCanMag 2021 CLC on Drug Plan Partnerships examined the evolution of health economics & formulary decision-making in Canadian private drug plans. Managed formularies help manage drug plan costs, but also present potential financial & legal risks https://t.co/RJ2VeFbzT2
IQVIA Canada PRA subscribers – check out the May 2021 issue for 2 articles I co-authored:
(1) BC - Private and Public Payer Integration (with Brad Millson and Tommy Lan)
(2) Breaking Down the Facts About Private Drug Plan Costs (with @jfarago1)
A great read from @BenCanMag that speaks to the need for specialty drug prior authorization – when prior authorization is delayed or declined, plan members' conditions can worsen. Learn more 👉 https://t.co/Og6oEinnfY
The private-payer perspective matters when assessing the value of a medication – and pharmacoeconomic analysis can be a tool in the private-payer decision making process. Learn more from the @BenCanMag 2020 Face to Face Drug Plan Management Forum. 👉 https://t.co/DxGvL4mCvL